Targeting ERAP1: Altering Neoantigen Presentation With a Small Molecule

By | 6th May 2022

Tumor visibility, defined as the level of tumor-specific antigen expression, is shown to strongly correlate with response to checkpoint inhibition and is a vital aspect determining the immunogenicity within the tumor microenvironment
Grey Wolf have developed inhibitors of ERAP1, an aminopeptidase in the antigen presentation pathway that determines which antigens are presented on the surface of a cell or tumor
As opposed to developing a vaccine, Grey Wolf ERAP1 small molecule inhibitors alter the immunopeptidome and thus visibility of the tumor, triggering a differentiated T cell response and causing tumor growth inhibition